PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Ceftazidime-Avibactam Use in a Cohort of Children with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development Following Difficult-to-Treat or Recurrent Infections
Version 1
: Received: 22 May 2024 / Approved: 23 May 2024 / Online: 23 May 2024 (07:18:59 CEST)
How to cite:
García-Boyano, M.; Alós Díez, M.; Fernández Tomé, L.; Escosa-García, L.; Moreno Ramos, F.; Schuffelmann-Gutiérrez, C.; Cendejas Bueno, E.; Calvo, C.; Baquero-Artigao, F.; Frauca Remacha, E. Ceftazidime-Avibactam Use in a Cohort of Children with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development Following Difficult-to-Treat or Recurrent Infections. Preprints2024, 2024051492. https://doi.org/10.20944/preprints202405.1492.v1
García-Boyano, M.; Alós Díez, M.; Fernández Tomé, L.; Escosa-García, L.; Moreno Ramos, F.; Schuffelmann-Gutiérrez, C.; Cendejas Bueno, E.; Calvo, C.; Baquero-Artigao, F.; Frauca Remacha, E. Ceftazidime-Avibactam Use in a Cohort of Children with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development Following Difficult-to-Treat or Recurrent Infections. Preprints 2024, 2024051492. https://doi.org/10.20944/preprints202405.1492.v1
García-Boyano, M.; Alós Díez, M.; Fernández Tomé, L.; Escosa-García, L.; Moreno Ramos, F.; Schuffelmann-Gutiérrez, C.; Cendejas Bueno, E.; Calvo, C.; Baquero-Artigao, F.; Frauca Remacha, E. Ceftazidime-Avibactam Use in a Cohort of Children with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development Following Difficult-to-Treat or Recurrent Infections. Preprints2024, 2024051492. https://doi.org/10.20944/preprints202405.1492.v1
APA Style
García-Boyano, M., Alós Díez, M., Fernández Tomé, L., Escosa-García, L., Moreno Ramos, F., Schuffelmann-Gutiérrez, C., Cendejas Bueno, E., Calvo, C., Baquero-Artigao, F., & Frauca Remacha, E. (2024). Ceftazidime-Avibactam Use in a Cohort of Children with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development Following Difficult-to-Treat or Recurrent Infections. Preprints. https://doi.org/10.20944/preprints202405.1492.v1
Chicago/Turabian Style
García-Boyano, M., Fernando Baquero-Artigao and Esteban Frauca Remacha. 2024 "Ceftazidime-Avibactam Use in a Cohort of Children with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development Following Difficult-to-Treat or Recurrent Infections" Preprints. https://doi.org/10.20944/preprints202405.1492.v1
Abstract
The prevalence of multidrug-resistant Gram-negative infections, particularly carbapenem-resistant strains, has become a significant global health concern. Ceftazidime-avibactam (CZA) has emerged as a promising treatment option. However, data on its efficacy and safety in children are scarce, necessitating further investigation. We conducted a retrospective study at a tertiary hospital in Spain from February 2019 to January 2022. Pediatric patients (<16 years) treated with CZA for confirmed or suspected multidrug-resistant Gram-negative infections were included. Clinical and microbiological characteristics, treatment approaches, and outcomes were examined. Eighteen children received CZA treatment. All had complex chronic conditions, with the most frequent underlying main diseases being liver transplantation (n=8) and biliary atresia (n=4). The predominant type of infection for which they received CZA was intra-abdominal infections caused or suspected to be caused by OXA-48-producing Klebsiella pneumoniae. CZA was generally well tolerated. Within the first month of starting CZA therapy, 2 patients died, with one case directly linked to the infection’s fatal outcome. Some patients needed repeated courses of therapy due to recurrent infections, yet no resistance development was noted. In summary, the use of CZA showed effectiveness and safety, while the lack of resistance development highlights CZA’s potential as a primary treatment option against OXA-48-producing infections.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
